Related references
Note: Only part of the references are listed.Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer
Bin Zhao et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT
Mattijs Out et al.
PHARMACOGENOMICS (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
Begoña Martin-Castillo et al.
Oncotarget (2018)
Repurposing metformin for the prevention of cancer and cancer recurrence
Brandy M. Heckman-Stoddard et al.
DIABETOLOGIA (2017)
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
Michele Reni et al.
CLINICAL CANCER RESEARCH (2016)
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
Navdeep S. Chandel et al.
CELL METABOLISM (2016)
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
Kaixin Zhou et al.
NATURE GENETICS (2016)
Metformin and cancer: Quo vadis et cui bono?
Javier A. Menendez et al.
ONCOTARGET (2016)
Repurposing metformin for cancer treatment: current clinical studies
Young Kwang Chae et al.
ONCOTARGET (2016)
Genomic Characterization of Metformin Hepatic Response
Marcelo R. Luizon et al.
PLOS GENETICS (2016)
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis
Kristine R. Broglio et al.
JAMA ONCOLOGY (2016)
Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32
Pamela J. Goodwin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Sil Kordes et al.
LANCET ONCOLOGY (2015)
Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis
Hong Xu et al.
ONCOLOGIST (2015)
Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32
Pamela J. Goodwin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Metformin: From Mechanisms of Action to Therapies
Marc Foretz et al.
CELL METABOLISM (2014)
Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
Alastair M. Thompson
CLINICAL CANCER RESEARCH (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
Silvia Cufi et al.
ONCOTARGET (2013)
The C Allele of ATM rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program
Jose C. Florez et al.
DIABETES CARE (2012)
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts
N. van Leeuwen et al.
DIABETOLOGIA (2012)
Metformin in cancer: translational challenges
Ryan J. O. Dowling et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2012)
Understanding the benefit of metformin use in cancer treatment
Ryan J. O. Dowling et al.
BMC MEDICINE (2011)
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
Pamela J. Goodwin et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
Kaixin Zhou et al.
NATURE GENETICS (2011)
Metformin: Multi-faceted protection against cancer
Sonia Del Barco et al.
ONCOTARGET (2011)
Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology
B. Martin-Castillo et al.
ANNALS OF ONCOLOGY (2010)
Metformin: A Therapeutic Opportunity in Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2010)
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Sao Jiralerspong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CANCER When restriction is good
Anne Brunet
NATURE (2009)
Tumours with PI3K activation are resistant to dietary restriction
Nada Y. Kalaany et al.
NATURE (2009)
Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: A population study
JM Fernandez-Real et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Share Paper
